Crinetics Pharmaceuticals, Inc. (CRNX) Stock Score, Valuation & Financial Research
Crinetics Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for CRNX
Crinetics Pharmaceuticals, Inc. currently has a Wall Street Score of 27/100. The stored market price is $84.95. Its financial score is 20/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Crinetics Pharmaceuticals, Inc. does
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical t
CRNX financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $84.95
- Market capitalization:
- $9.00B
- Revenue:
- $42.2M
- Net income:
- $-501.6M
- Free cash flow:
- $-383.7M
- Cash:
- $55.5M
- Total debt:
- $47.2M
- EPS:
- -5.05
- Financial score:
- 20/100
- Valuation score:
- 0/100
- Revenue score:
- 40/100
What stands out
- Reported year-over-year revenue growth is +4.5%.
- Free cash flow is $-383.7M, showing cash burn in the current stored period.
- The balance sheet shows $55.5M of cash versus $47.2M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 20/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CRNX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.